<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:mp ids='MP_0005048'>Thrombosis</z:mp> after arterial injury is often initiated by <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWF)-dependent platelet accumulation </plain></SENT>
<SENT sid="1" pm="."><plain>A promising antithrombotic strategy is the interruption of platelet/vWF interactions </plain></SENT>
<SENT sid="2" pm="."><plain>Previously, we demonstrated how chemical and affinity modification can enhance <z:chebi fb="5" ids="28304">heparin</z:chebi>'s anti-vWF activity while reducing conventional anticoagulation </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we investigated whether a modified <z:chebi fb="5" ids="28304">heparin</z:chebi> can block platelet-dominated <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Standard <z:chebi fb="5" ids="28304">heparin</z:chebi> was oxidized with <z:chebi fb="1" ids="49826">periodate</z:chebi>, refined to have high vWF affinity and inhibitory potency, and tested in a guinea pig model of platelet-dependent <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In this model, a controlled mechanical arterial injury yields cyclic flow variations (CFVs) caused by recurrent accumulation of platelet <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> six control animals developed CFVs (mean, 10.4 +/- 2.6 CFVs), and six of seven animals treated with standard <z:chebi fb="5" ids="28304">heparin</z:chebi> also developed CFVs (mean, 7.6 +/- 4.6) </plain></SENT>
<SENT sid="7" pm="."><plain>Only one of six animals treated with the anti-vWF <z:chebi fb="5" ids="28304">heparin</z:chebi> and one of six treated with AJvW-2 (an anti-vWF antibody) developed CFVs (mean, 2.0 +/- 4.9 and 0.5 +/- 1.2, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>Thus both the modified <z:chebi fb="5" ids="28304">heparin</z:chebi> and AJvW-2 were more effective than standard <z:chebi fb="5" ids="28304">heparin</z:chebi> (p &lt; 0.03) </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> times and platelet counts were unaffected </plain></SENT>
<SENT sid="10" pm="."><plain>A modified activated partial thromboplastin time was less prolonged by the modified high-affinity <z:chebi fb="5" ids="28304">heparin</z:chebi> (91 +/- 17) seconds) than by standard <z:chebi fb="5" ids="28304">heparin</z:chebi> (144 +/- 30 seconds; p &lt; 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The modified <z:chebi fb="5" ids="28304">heparin</z:chebi> with high vWF affinity was a more effective arterial antithrombotic agent, with fewer conventional <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> effects than standard <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Interruption of the vWF/platelet interaction is a promising antithrombotic strategy that may be met by novel <z:chebi fb="5" ids="28304">heparin</z:chebi>-based antithrombotic drugs </plain></SENT>
</text></document>